PFIC - Progressive Familial Intrahepatic CholestasisREGENICNCT07191704
A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain
An observational study of PFIC - Progressive Familial Intrahepatic Cholestasis, run by Ipsen at 10 sites in Spain.
Trial summary
Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of inherited conditions that affect how bile moves in the liver, which can lead to serious liver problems. Doctors usually recommend genetic testing for patients with unexplained bile issues-after ruling out more common causes-to better understand the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PFIC - Progressive Familial Intrahepatic Cholestasis
- How many people
- 150 participants
- Where
- 10 sitesSpain
- Study dates
- 8 Dec 2025to 3 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 150 patients, both male and female, of age (≥ 18 years) with unexplained recurrent and/or chronic cholestasis (idiopathic cholestasis) will be recruited
Who may be able to join
- Adult patients (≥18 years old) with written informed consent prior to data collection and study procedures.
- Unexplained recurrent and/or chronic cholestasis (idiopathic cholestasis), defined as alkaline phosphatase (ALP) or Gamma-Glutamyl Transferase (GGT) > Upper Limit of Normal (ULN).
- Patients who provide the blood sample for the genetic analysis.
Who cannot join
- Patients with clear and confirmed diagnosed causes of cholestasis, including:
- Primary Biliary Cholangitis
- Primary or Secondary Sclerosing Cholangitis
- Obstruction of the bile ducts
- Other Liver diseases: cholestasis secondary to hepatocellular injury, viral hepatitis (mainly Hepatitis A virus [HAV], Hepatitis B virus [HBV] and Hepatitis C virus [HCV]), toxic hepatitis (pharmacological; drug-induced liver injury [DILI]), autoimmune hepatitis; intestinal failure, total parenteral nutrition [TPN]; Wilson's disease, choledochal cyst, Caroli Syndrome, and thick bile due to haemolysis.
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
Spain10 sites
H. Clinic (first CEIm)
Barcelona
H. Vall Hebron
Barcelona
H. Reina Sofía
Córdoba
H. Dr. Negrín
Las Palmas
H. Gregorio Marañón
Madrid
Hospital Universitario La Paz
Madrid
H. Virgen del Rocío
Seville
H. La Fe
Valencia
H. Río Hortega
Valladolid
H. Miguel Servet
Zaragoza
About this study
Official title: Characterization of Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes in Adult Patients With Idiopathic Recurrent and Chronic Cholestasis in Spain - REGENIC
Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of inherited conditions that affect how bile moves in the liver, which can lead to serious liver problems. Doctors usually recommend genetic testing for patients with unexplained bile issues-after ruling out more common causes-to better understand the problem. However, there isn't much information on how common these genetic changes are in adults with these liver issues, especially in Spain. This study will observe these genetic changes so that doctors can diagnose the condition more clearly and create personalized treatment plans.
This study will be conducted in several centers across Spain for 10 months. Each adult participant will take part in a single-day visit where their health information will be collected, and a blood sample will be taken for both routine tests and genetic analysis.
- Keywords
- Cholestasis
- Medical subject headings
- Cholestasis, progressive familial intrahepatic 1, Cholestasis
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants with at least One Variant in PFIC-Related Genes
Defined as the percentage of participants with at least one variant in PFIC-related genes in relation to the total number of participants with idiopathic recurrent and/or chronic cholestasis of the study cohort as an assessment of prevalence.
Measured: At enrollment
Secondary outcomes (30)
Percentage of Participants Carrying Each Identified Variant of Genes related to PFIC
Defined as the percentage of participants carrying each identified variant of genes related to PFIC.
Measured: At enrollment
Demographic Data: Age at Enrollment
Defined as the mean age of participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Demographic Data: Sex at Enrollment
Defined as the count of sex of participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Demographic Data: Race/Ethnicity at Enrollment
Defined as the race/ethnicity of participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Demographic Data: Weight at Enrollment
Defined as the mean weight participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Demographic Data: Height at Enrollment
Defined as the mean height participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Demographic Data: Body Mass Index (BMI) at Enrollment
Defined as the mean BMI, calculated by dividing participant's weight in kilograms by the square of their height in meters (BMI = weight ÷ height²), as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Demographic Data: Alcohol Consumption at Enrollment
Defined as the mean of standard drinks in a week to assess the alcohol consumption, recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Age at Cholestasis Diagnosis
Defined as the mean participant's age when first symptoms were reported, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
History of Liver Disease
Defined as the count of presence of liver conditions such as gallstones, pancreatitis, and cirrhosis (among other relevant conditions), as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
History of Diagnostic Procedures Used
Defined as the count of presence of diagnostic procedures performed, including liver biopsy and elastography (Fibroscan) as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Presence of Liver Disease Symptoms
Defined as the count of presence of liver condition symptoms such as jaundice, pruritus and disease-related fatigue, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
History of liver or biliary disease related surgeries
Defined as the count of history of liver or biliary disease related surgeries, such as cholecystectomy, liver transplantation, surgical biliary diversion (SBD) or other liver-related surgery, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Family history of liver disease
Defined as the count of family history of liver disease, such as the presence or absence of PFIC, intrahepatic cholestasis of pregnancy (ICP), benign recurrent intrahepatic cholestasis (BRIC), low-phospholipid-associated cholelithiasis (LPAC), portal hypertension, hepatocellular carcinoma, cholangiocarcinoma, pancreatitis, gallstones, cirrhosis, cholestatic drug induced liver injury (DILI), Metabolic dysfunction-associated fatty liver disease (MASLD), Non-alcoholic Steatohepatitis (MASH) and any other chronic liver disease, and which close relative has suffered it (parent, grandparent, sibling, etc.), as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Presence or Absence of Fat-Soluble Vitamin deficiencies
Defined as the count of presence or absence of vitamin deficiencies, such as vitamin A, D, E and K and supplementation, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Haematology - Haemoglobin
Defined as the last recorded routine analysis of haemoglobin, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Haematology - Red Blood Cell (RBC) count
Defined as the last recorded routine analysis of RBC count, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Haematology - Leukocytes
Defined as the last recorded routine analysis of leukocytes, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Haematology - Platelets
Defined as the last recorded routine analysis of platelets, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Chemistry - Alanine aminotransferase (ALT)
Defined as the recorded routine analysis of ALT, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Chemistry - Aspartate aminotransferase (AST)
Defined as the recorded routine analysis of AST, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Chemistry - Alkaline Phosphatase (ALP)
Defined as the recorded routine analysis of ALP, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Chemistry - Total and direct bilirubin
Defined as the recorded routine analysis of total and direct bilirubin, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Chemistry - Bile Acids (sBA)
Defined as the recorded routine analysis of sBA, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Chemistry - Gamma-Glutamyl Transferase (GGT)
Defined as the recorded routine analysis of GGT, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Chemistry - Albumin
Defined as the recorded routine analysis of albumin, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Coagulation - Prothrombin time
Defined as the recorded routine analysis of prothrombin time, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Laboratory Analysis of Coagulation - International Normalized Ratio (INR)
Defined as the recorded routine analysis of INR, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Frequency of Prior and Concomitant treatment for cholestatic liver disease and pruritus.
Defined as the count of prior and concomitant treatment for cholestatic liver disease and pruritus: ursodeoxycholic acid (UDCA), cholestyramine, rifampicin, fibrates, ileal bile acid transporter inhibitors (IBATi), selective serotonin reuptake inhibitors (SSRI), opioid antagonists, Chaperones (4- phenylbutyrate, [4-PB]) skin emollients or others, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Comorbidities of interest (i.e., diabetes, metabolic syndrome, osteopenia/osteoporosis)
Defined as the count of comorbidities of interest, such as diabetes, metabolic syndrome, osteopenia/osteoporosis, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.
Measured: At enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2025
- Study start8 Dec 2025
- Primary completion3 Jun 2026
- Study completion3 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PFIC - Progressive Familial Intrahepatic CholestasisStudies of the same condition, open and under way.
- More trials run by IpsenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ipsen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ipsen Medical Director, Study director, Ipsen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07191704
- Sponsor's protocol ID
- CLIN-60240-453
- Acronym
- REGENIC
- Status last verified
- Jul 2026
- First submitted
- 17 Sep 2025
- Last updated
- 3 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterization of Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes in Adult Patients With Idiopathic Recurrent and Chronic Cholestasis in Spain - REGENIC
- ClinicalTrials.gov ID
- NCT07191704
- Acronym / sponsor ID
- REGENIC / CLIN-60240-453
- Keywords
- Cholestasis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- IpsenIndustry (pharma, biotech, devices)
- Study start
- 8 Dec 2025 (actual)
- Primary completion
- 3 Jun 2026 (actual)
- Study completion
- 3 Jun 2026 (actual)
- First posted
- 25 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of inherited conditions that affect how bile moves in the liver, which can lead to serious liver problems. Doctors usually recommend genetic testing for patients with unexplained bile issues-after ruling out more common causes-to better understand the problem. However, there isn't much information on how common these genetic changes are in adults with these liver issues, especially in Spain. This study will observe these genetic changes so that doctors can diagnose the condition more clearly and create personalized treatment plans.
This study will be conducted in several centers across Spain for 10 months. Each adult participant will take part in a single-day visit where their health information will be collected, and a blood sample will be taken for both routine tests and genetic analysis.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 150 patients, both male and female, of age (≥ 18 years) with unexplained recurrent and/or chronic cholestasis (idiopathic cholestasis) will be recruited
Key inclusion criteria (3 listed)
- Adult patients (≥18 years old) with written informed consent prior to data collection and study procedures.
- Unexplained recurrent and/or chronic cholestasis (idiopathic cholestasis), defined as alkaline phosphatase (ALP) or Gamma-Glutamyl Transferase (GGT) > Upper Limit of Normal (ULN).
- Patients who provide the blood sample for the genetic analysis.
Key exclusion criteria (5 listed)
- Patients with clear and confirmed diagnosed causes of cholestasis, including:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of Participants with at least One Variant in PFIC-Related Genes
Time frame: At enrollment
Defined as the percentage of participants with at least one variant in PFIC-related genes in relation to the total number of participants with idiopathic recurrent and/or chronic cholestasis of the study cohort as an assessment of prevalence.
30 secondary outcomes
Percentage of Participants Carrying Each Identified Variant of Genes related to PFIC
Time frame: At enrollment
Demographic Data: Age at Enrollment
Time frame: At enrollment
Demographic Data: Sex at Enrollment
Time frame: At enrollment
Demographic Data: Race/Ethnicity at Enrollment
Time frame: At enrollment
Demographic Data: Weight at Enrollment
Time frame: At enrollment
Demographic Data: Height at Enrollment
Time frame: At enrollment
Demographic Data: Body Mass Index (BMI) at Enrollment
Time frame: At enrollment
Demographic Data: Alcohol Consumption at Enrollment
Time frame: At enrollment
Age at Cholestasis Diagnosis
Time frame: At enrollment
History of Liver Disease
Time frame: At enrollment
History of Diagnostic Procedures Used
Time frame: At enrollment
Presence of Liver Disease Symptoms
Time frame: At enrollment
History of liver or biliary disease related surgeries
Time frame: At enrollment
Family history of liver disease
Time frame: At enrollment
Presence or Absence of Fat-Soluble Vitamin deficiencies
Time frame: At enrollment
Laboratory Analysis of Haematology - Haemoglobin
Time frame: At enrollment
Laboratory Analysis of Haematology - Red Blood Cell (RBC) count
Time frame: At enrollment
Laboratory Analysis of Haematology - Leukocytes
Time frame: At enrollment
Laboratory Analysis of Haematology - Platelets
Time frame: At enrollment
Laboratory Analysis of Chemistry - Alanine aminotransferase (ALT)
Time frame: At enrollment
Laboratory Analysis of Chemistry - Aspartate aminotransferase (AST)
Time frame: At enrollment
Laboratory Analysis of Chemistry - Alkaline Phosphatase (ALP)
Time frame: At enrollment
Laboratory Analysis of Chemistry - Total and direct bilirubin
Time frame: At enrollment
Laboratory Analysis of Chemistry - Bile Acids (sBA)
Time frame: At enrollment
Laboratory Analysis of Chemistry - Gamma-Glutamyl Transferase (GGT)
Time frame: At enrollment
Laboratory Analysis of Chemistry - Albumin
Time frame: At enrollment
Laboratory Analysis of Coagulation - Prothrombin time
Time frame: At enrollment
Laboratory Analysis of Coagulation - International Normalized Ratio (INR)
Time frame: At enrollment
Frequency of Prior and Concomitant treatment for cholestatic liver disease and pruritus.
Time frame: At enrollment
Comorbidities of interest (i.e., diabetes, metabolic syndrome, osteopenia/osteoporosis)
Time frame: At enrollment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Related trials for PFIC - Progressive Familial Intrahepatic Cholestasis
Active, not recruitingObservational study
Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)
PFIC - Progressive Familial Intrahepatic Cholestasis
RecruitingObservational study
Pediatric Evaluation and Registry for Liver Cholestasis in Canada
PFIC - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome (ALGS)
RecruitingObservational study
A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC)
RecruitingObservational study
Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers
Hepatobiliary Cancers, Progressive Familial Intrahepatic Cholestasis (PFIC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ipsen Medical Director study director
Ipsen
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of PFIC - Progressive Familial Intrahepatic Cholestasis, run by Ipsen at 10 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants with at least One Variant in PFIC-Related Genes (time frame: At enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026; AzTrials last refreshed its copy on 31 Oct 2026.